Your browser doesn't support javascript.
loading
A pharmacokinetic approach to model-guided design of infliximab schedules in ulcerative colitis patients / Aproximación al diseño de un programa de administración de infliximab a pacientes con colitis ulcerosa basado en un modelo famacocinético
Pérez-Pitarch, Alejandro; Ferriols-Lisart, Rafael; Alós-Almiñana, Manuel; Mínguez-Pérez, Miguel.
Affiliation
  • Pérez-Pitarch, Alejandro; Hospital Clínico Universitario. Pharmacy Department. Valencia. España
  • Ferriols-Lisart, Rafael; Hospital Clínico Universitario. Pharmacy Department. Valencia. España
  • Alós-Almiñana, Manuel; Hospital Clínico Universitario. Pharmacy Department. Valencia. España
  • Mínguez-Pérez, Miguel; Universidad de Valencia. Valencia. España
Rev. esp. enferm. dig ; 107(3): 137-142, mar. 2015. tab, graf
Article in English | IBECS | ID: ibc-133837
Responsible library: ES1.1
Localization: BNCS
ABSTRACT

BACKGROUND:

Infliximab, an anti-tumour necrosis factor approved for treatment of Crohn's disease and ulcerative colitis, is administered at predefined interdose-intervals. On insufficient response or loss of response, treatment can be intensified. The lack or loss of response is likely related to complex pharmacokinetics of infliximab.

AIMS:

To explore optimal dosing strategies of infliximab in treatment-naïve patients with ulcerative colitis through predictive Monte Carlo simulations based on a validated population PK model.

METHODS:

A population of 2,000 treatment-naïve patients was generated by Montecarlo simulation. Six dosing strategies for maintenance therapy were simulated on this population. Strategies 1 and 2 consisted on 5 mg/kg and 6 mg/kg doses, respectively, and 8 weeks inter-dose interval. Strategies 3 and 4 used Individualized doses, adjusted to albumin level, sex and body weight, and a fix interdose interval of 8 weeks to achieve a target trough concentration of 5 mg/L or 6 mg/L, respectively. Strategies 5 and 6 used a fix dose of 5 mg/kg and individualized inter-dose intervals, adjusted to the same covariates, to achieve a target concentration, of 5 mg/L or 6 mg/L, respectively.

RESULTS:

Strategies 2-6 reached trough levels statistically higher than strategy 1 (p < 0.05). Strategy 5 proved to be the best dosing strategy. It was associated with a higher proportion of responder patients than strategy 1 (62 % vs. 40 %) without reaching higher peak concentrations.

CONCLUSIONS:

Optimization of maintenance treatment of colitis with infliximab by a pharmacokinetic approach could benefit infliximab-naive patients with ulcerative colitis
RESUMEN
No disponible
Subject(s)
Full text: Available Collection: National databases / Spain Database: IBECS Main subject: Colitis, Ulcerative / Antibodies, Monoclonal, Murine-Derived Type of study: Prognostic study Limits: Humans Language: English Journal: Rev. esp. enferm. dig Year: 2015 Document type: Article Institution/Affiliation country: Hospital Clínico Universitario/España / Universidad de Valencia/España
Full text: Available Collection: National databases / Spain Database: IBECS Main subject: Colitis, Ulcerative / Antibodies, Monoclonal, Murine-Derived Type of study: Prognostic study Limits: Humans Language: English Journal: Rev. esp. enferm. dig Year: 2015 Document type: Article Institution/Affiliation country: Hospital Clínico Universitario/España / Universidad de Valencia/España
...